4/7
01:45 pm
cvkd
Cadrenal Therapeutics (CVKD) had its price target lowered by HC Wainwright from $32.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
Cadrenal Therapeutics (CVKD) had its price target lowered by HC Wainwright from $32.00 to $13.00. They now have a "buy" rating on the stock.
3/31
08:45 am
cvkd
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
High
Report
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
3/12
08:00 am
cvkd
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
Medium
Report
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
3/2
08:28 am
cvkd
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion [Yahoo! Finance]
Low
Report
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion [Yahoo! Finance]
3/2
08:00 am
cvkd
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Low
Report
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
2/25
04:42 pm
cvkd
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events [Yahoo! Finance]
Medium
Report
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events [Yahoo! Finance]
2/24
08:30 am
cvkd
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
High
Report
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement